PE20151751A1 - Metodos de tratamiento de la deficiencia de hierro con pirofosfato ferrico soluble - Google Patents
Metodos de tratamiento de la deficiencia de hierro con pirofosfato ferrico solubleInfo
- Publication number
- PE20151751A1 PE20151751A1 PE2015001600A PE2015001600A PE20151751A1 PE 20151751 A1 PE20151751 A1 PE 20151751A1 PE 2015001600 A PE2015001600 A PE 2015001600A PE 2015001600 A PE2015001600 A PE 2015001600A PE 20151751 A1 PE20151751 A1 PE 20151751A1
- Authority
- PE
- Peru
- Prior art keywords
- methods
- iron deficiency
- ferric pyrophosphate
- treatment
- soluble ferric
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/42—Phosphorus; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1816—Erythropoietin [EPO]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Obesity (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Molecular Biology (AREA)
Abstract
La invencion proporciona metodos de tratamiento de la deficiencia de hierro y metodos para reducir o eliminar la dosis de agente estimulante de la eritropoyesis para aumentar o mantener los niveles de hemoglobina en el rango objetivo en un sujeto que sufre de anemia, que comprende administrar pirofosfato ferrico soluble en una cantidad eficaz para mantener o aumentar los niveles de hemoglobina en el sujeto
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361759531P | 2013-02-01 | 2013-02-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20151751A1 true PE20151751A1 (es) | 2015-12-03 |
Family
ID=50097899
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2015001600A PE20151751A1 (es) | 2013-02-01 | 2014-02-01 | Metodos de tratamiento de la deficiencia de hierro con pirofosfato ferrico soluble |
Country Status (20)
Country | Link |
---|---|
US (3) | US20150366907A1 (es) |
EP (2) | EP2950806B1 (es) |
JP (3) | JP2016507527A (es) |
KR (1) | KR102236714B1 (es) |
CN (2) | CN107007624A (es) |
AU (3) | AU2014212127A1 (es) |
BR (1) | BR112015018549A8 (es) |
CA (1) | CA2900043A1 (es) |
CL (1) | CL2015002171A1 (es) |
EA (1) | EA032407B1 (es) |
HK (1) | HK1215185A1 (es) |
IL (1) | IL240257A0 (es) |
MX (1) | MX370139B (es) |
NI (1) | NI201500100A (es) |
PE (1) | PE20151751A1 (es) |
PH (1) | PH12015501708A1 (es) |
SG (1) | SG11201506022VA (es) |
TW (1) | TW201517913A (es) |
WO (1) | WO2014121155A1 (es) |
ZA (1) | ZA201506364B (es) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9980894B2 (en) | 2012-06-15 | 2018-05-29 | Symrise Ag | Cosmetic compositions comprising hyaluronan biosynthesis promoting agents |
KR20160091918A (ko) * | 2013-11-05 | 2016-08-03 | 락웰 메디컬, 인코포레이티드 | 저반응성 환자에서 에리스로포이에틴 자극제의 용량을 감소시키는 방법 |
US11517555B2 (en) * | 2015-09-04 | 2022-12-06 | Rockwell Medical, Inc. | Solid soluble ferric pyrophosphate formulations, kits, and methods using the same |
CN106581053A (zh) * | 2015-10-20 | 2017-04-26 | 华仁药业股份有限公司 | 一种具有补铁功能的腹膜透析液 |
EP3842808A4 (en) * | 2018-08-24 | 2022-05-18 | National University Corporation Yokohama National University | ADMINISTRATION MANAGEMENT APPARATUS, ADMINISTRATION MANAGEMENT METHOD AND PROGRAM |
US11278651B2 (en) * | 2018-10-17 | 2022-03-22 | Gambro Lundia Ab | Membrane and device for treating restless leg syndrome |
CN110063965A (zh) * | 2019-06-04 | 2019-07-30 | 吉林省富生医疗器械有限公司 | 一种血液透析浓缩物 |
WO2021163209A1 (en) * | 2020-02-11 | 2021-08-19 | Quest Diagnostics Investments Llc | System for determining an underlying cause of anemia |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR9713653B1 (pt) | 1996-12-31 | 2013-05-21 | composiÇço farmacÊutica, mÉtodo para preparar uma composiÇço farmacÊutica, e, uso de pirofosfato fÉrrico. | |
US6689275B1 (en) | 1996-12-31 | 2004-02-10 | Ajay Gupta | Method and pharmaceutical composition for replacing iron losses in dialysis patients |
US6779468B1 (en) | 1997-08-07 | 2004-08-24 | Ajay Gupta | Method and pharmaceutical composition for iron delivery in hemodialysis and peritoneal dialysis patients |
US6779648B2 (en) * | 2000-07-13 | 2004-08-24 | Psi Sales, Inc. | 360 Degree rotatable lifter arm for log singulator |
JP2005068055A (ja) * | 2003-08-22 | 2005-03-17 | Fujiyakuhin Co Ltd | 無機元素含有水性コロイド分散液 |
US7857977B2 (en) * | 2005-07-12 | 2010-12-28 | Rockwell Medical Technologies, Inc. | Packaging of ferric pyrophosphate for dialysis |
ES2634142T3 (es) * | 2005-12-23 | 2017-09-26 | Ajay Gupta | Composición de nutrición parenteral que contiene hierro |
US7816404B2 (en) * | 2007-07-20 | 2010-10-19 | Rockwell Medical Technologies, Inc. | Methods for the preparation and use of ferric pyrophosphate citrate chelate compositions |
US8178709B2 (en) * | 2009-07-21 | 2012-05-15 | Biolink Life Sciences, Inc. | Iron preparation suitable for pharmaceutical formulation and process for the preparation thereof |
CA2819234A1 (en) * | 2011-01-07 | 2012-07-12 | Merrion Research Iii Limited | Pharmaceutical compositions of iron for oral administration |
-
2014
- 2014-02-01 EA EA201591424A patent/EA032407B1/ru unknown
- 2014-02-01 WO PCT/US2014/014341 patent/WO2014121155A1/en active Application Filing
- 2014-02-01 CN CN201710166250.6A patent/CN107007624A/zh active Pending
- 2014-02-01 EP EP14704273.3A patent/EP2950806B1/en active Active
- 2014-02-01 BR BR112015018549A patent/BR112015018549A8/pt not_active Application Discontinuation
- 2014-02-01 AU AU2014212127A patent/AU2014212127A1/en not_active Abandoned
- 2014-02-01 US US14/765,111 patent/US20150366907A1/en not_active Abandoned
- 2014-02-01 KR KR1020157022737A patent/KR102236714B1/ko active IP Right Grant
- 2014-02-01 MX MX2015009968A patent/MX370139B/es active IP Right Grant
- 2014-02-01 CN CN201480003130.9A patent/CN104936609B/zh active Active
- 2014-02-01 PE PE2015001600A patent/PE20151751A1/es unknown
- 2014-02-01 JP JP2015556190A patent/JP2016507527A/ja active Pending
- 2014-02-01 EP EP20185823.0A patent/EP3789034A1/en not_active Withdrawn
- 2014-02-01 CA CA2900043A patent/CA2900043A1/en not_active Abandoned
- 2014-02-01 SG SG11201506022VA patent/SG11201506022VA/en unknown
- 2014-02-05 TW TW103103727A patent/TW201517913A/zh unknown
-
2015
- 2015-07-30 IL IL240257A patent/IL240257A0/en unknown
- 2015-07-31 PH PH12015501708A patent/PH12015501708A1/en unknown
- 2015-07-31 NI NI201500100A patent/NI201500100A/es unknown
- 2015-08-03 CL CL2015002171A patent/CL2015002171A1/es unknown
- 2015-08-31 ZA ZA2015/06364A patent/ZA201506364B/en unknown
-
2016
- 2016-03-21 HK HK16103233.3A patent/HK1215185A1/zh not_active IP Right Cessation
-
2017
- 2017-11-10 US US15/809,734 patent/US20180280432A1/en not_active Abandoned
-
2018
- 2018-12-12 AU AU2018278891A patent/AU2018278891B2/en not_active Ceased
-
2019
- 2019-06-18 JP JP2019112699A patent/JP2019151669A/ja active Pending
-
2020
- 2020-05-18 US US16/877,086 patent/US20200276232A1/en not_active Abandoned
- 2020-12-09 AU AU2020286223A patent/AU2020286223A1/en not_active Abandoned
-
2021
- 2021-07-26 JP JP2021121654A patent/JP2021169525A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20151751A1 (es) | Metodos de tratamiento de la deficiencia de hierro con pirofosfato ferrico soluble | |
CO2019008487A2 (es) | Compuesto de quinazolina | |
PH12017500070A1 (en) | Methods of treating cancer using tigit inhibitors and anti-cancer agents | |
EA201690980A1 (ru) | Комбинированная терапия, включающая ингибитор mdm2 и один или более дополнительных фармацевтически активных агентов, для лечения различных видов рака | |
AR102553A1 (es) | Terapia de combinación con agonistas de unión ox40 e inhibidores de tigit | |
CL2015000699A1 (es) | Métodos para tratamiento de cáncer. | |
BR112017011536A2 (pt) | terapias de combinação | |
BR112015026297A2 (pt) | terapia combinada composta por um inibidor tor quinase e um composto de 5-quinazolinona substituído para o tratamento de câncer | |
CR20150376A (es) | Compuestos sustituidos de pirrolopirimidina, compuestos de los mismos y metodos de tratamiento con los mismos | |
MX2016007351A (es) | Terapia de combinacion para tratar cancer. | |
MX2016008131A (es) | Compuestos heterociclos biciclicos y sus usos en terapia. | |
EA201992251A1 (ru) | Противораковые вакцины и способы лечения с их применением | |
MX2022014277A (es) | Metodos para una mejor administracion de agentes activos a tumores. | |
EA201500996A1 (ru) | Терапевтические применения эмпаглифлозина | |
BR112015026021A2 (pt) | terapia de combinação compreendendo um inibidor de tor quinase e n-(3-(5-flúor-2-(4-(2-met-oxietoxi)fenilamino)pirimidin-4-ilamino)fenil)acrilamida para o tratamento de câncer | |
MX2015014599A (es) | Terapia de combinacion que comprende un inhibidor de tor cinasa y un analogo de citidina para tracar cancer. | |
EA201591987A1 (ru) | Лечение злокачественной опухоли дигидропиразинопиразинами | |
PH12015502616A1 (en) | Pharmaceutical combination comprising metformin and dihydroquercetin and its use for the treatment of cancer | |
MX2018010223A (es) | Terapia combinada para tratamiento de cancer de ovario. | |
MY197664A (en) | Immunity enhancing agent for cancer by allergin-1 antagonist | |
MX2017013666A (es) | Terapia de combinacion de agente anti-fuctactico y agente de inmunoterapia y composiciones para el tratamiento de cancer. | |
MX2020002585A (es) | Inhibidor de hdac combinado con un modulador del punto de control inmunitario para la terapia contra el cancer. | |
WO2015168102A3 (en) | Prolonged protein stabilization by resveratrol | |
BR112015028334A2 (pt) | agente e método para o tratamento de herpes | |
MX2018015240A (es) | Composiciones que comprenden timolol y su uso en el tratamiento de rosacea mediante administracion topica. |